New combo therapy tested for deadly childhood brain cancer

NCT ID NCT01165333

Completed Disease control Sponsor: Centre Oscar Lambret Source: ClinicalTrials.gov ↗

First seen Mar 22, 2026 · Last updated May 22, 2026 · Updated 11 times

Summary

This study tested the safety of a drug called cilengitide when given together with radiation therapy to children and young adults with a rare and aggressive brain tumor called diffuse intrinsic pontine glioma (DIPG). The goal was to find the highest safe dose. 32 participants were enrolled. The study was completed and focused on side effects and how the drug moves through the body.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE INTRINSIC PONTINE GLIOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

CHU

Toulouse, 33059, France
CHU, Hôpital d'Enfants de la Timone

Marseille, 13385, France
Centre Hospitalier Universitaire de Nantes

Nantes, 44093, France
Centre Léon Bérard

Lyon, 69373, France
Centre Oscar Lambret

Lille, 59020, France
Hôpital des Enfants, Groupe Hospitalier

Bordeaux, 33076, France
Hôpitaux Universitaires de Strasbourg

Strasbourg, 67091, France
Institut Curie

Paris, 75231, France
Institut Gustave-Roussy

Villejuif, 94805, France

Conditions

Explore the condition pages connected to this study.

DIFFUSE INTRINSIC PONTINE GLIOMA